Clinical trials
Tomography clinical trials
Below are recruiting tomography clinical trials, each written for real people, not researchers. We’re tracking 842 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05146180Recruiting
Scan to help diagnose infection on a replaced heart valve
This study tests a special type of PET/CT scan to better detect infections on a prosthetic (replaced) heart valve. It may help doctors confirm whether infection is present, based on imaging results.
RouenAges 18 years+ - NCT05188872Recruiting
PET scan for adrenal hormone condition before and after treatment
This trial uses a special PET scan to look at a hormone gland condition called primary aldosteronism, which can cause high blood pressure. It aims to see if the scan helps doctors plan treatment and check results.
Fuzhou, FujianAges 19–90 - NCT05195385Recruiting
Lung cancer screening CT scan for women
This study checks how well a low-dose CT scan screening program works for women at higher risk of lung cancer. If you qualify, you’ll be screened and asked to return for follow-ups for about 2 years.
ParisAges 50–74 - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT05112601RecruitingPhase 2
Nivolumab plus or minus ipilimumab for dMMR endometrial cancer
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
Birmingham, AlabamaAges 18 years+ - NCT05053971RecruitingPhase 1/Phase 2
Entinostat plus ZEN003694 for advanced solid tumors
This Phase 1/2 study tests a new combination anti-cancer treatment (entinostat plus ZEN003694) in people with advanced solid tumors that can’t be controlled with standard care. It aims to find a safe dose and see whether the treatment can shrink tumors or control the disease.
New Haven, ConnecticutAges 18 years+ - NCT05030207Recruiting
Test a new CT scan method for lung cancer radiation planning
This study tests whether a real-time, breathing-adapted CT scan (called 4DCT) can be done safely and work well for planning radiation treatment for lung cancer. It may help make radiation planning more accurate while checking if the scan process is practical for patients.
Blacktown, New South WalesAges 18 years+ - NCT04949464Recruiting
Smoking quit coaching plus lung scans for people with HIV
This study tests a behavior-change program to help people with HIV quit smoking, along with routine low-dose lung CT scans to find warning signs early. It’s a feasibility study, meaning the main goal is to see if the approach is practical and acceptable, and if people can follow through.
La Jolla, CaliforniaAges 45–80 - NCT04983095Recruiting
Targeted radiation for a few prostate cancer metastases
This trial looks at whether a precise form of radiation (stereotactic body radiotherapy) can control a small number of prostate cancer spots seen on a special scan (PSMA PET/CT). It may help by treating limited metastases while avoiding unnecessary treatment elsewhere.
Lund, LundAges 18 years+ - NCT04941716RecruitingPhase 2
Acalabrutinib plus venetoclax for hard-to-treat CLL/SLL
This Phase 2 trial studies whether combining acalabrutinib and venetoclax can shrink or control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or did not respond to prior treatment. It may help by attacking the cancer using two different medicines together.
Seattle, WashingtonAges 18 years+ - NCT04858334RecruitingPhase 2
Olaparib after pancreatic cancer surgery for BRCA or PALB2 mutations
This trial studies whether olaparib (a targeted cancer medicine) can help prevent pancreatic cancer from coming back after surgery in people with BRCA1, BRCA2, or PALB2 mutations. You would get olaparib or a placebo (inactive pill) and be closely followed to see if recurrence is reduced.
Anchorage, AlaskaAges 18 years+ - NCT04861077RecruitingEarly Phase 1
PET/MRI monitoring for PD-L1–positive triple-negative breast cancer
This early-phase study uses advanced PET/MRI scans to monitor how immunotherapy treatment works in people with triple-negative breast cancer that is PD-L1 positive. It may help doctors better track tumor changes in the body over time.
Birmingham, AlabamaAges 18–75 - NCT04913311Recruiting
Testing markers to predict lung inflammation after lung cancer treatment
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
Houston, TexasAges Any age - NCT04629469Recruiting
Two types of MRI scans in children
This study compares two MRI scan settings (a lower and higher magnetic field) in children to see how well they work for pediatric patients. It may help doctors choose the best MRI approach for kids without changing any care beyond the scan itself.
Kansas City, MissouriAges birth–22 years - NCT04751409RecruitingPhase 2
Less versus more follow-up after sarcoma surgery
This trial compares two schedules of post-treatment check-ups to see which one better supports patient quality of life. You’d fill out surveys for up to two years to measure how you feel over time.
Houston, TexasAges 18 years+ - NCT04743362Recruiting
Noninvasive scans for skin and mouth lesions
This trial tests noninvasive imaging methods to look at skin and mouth (mucosal) conditions. It may help doctors better see changes in these areas without taking tissue samples.
New York, New YorkAges Any age - NCT04616560RecruitingPhase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Birmingham, AlabamaAges 12–39 - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Kingman, ArizonaAges 18 years+ - NCT04671667RecruitingPhase 2
Pembrolizumab vs chemo-radiation after surgery for recurrent head/neck cancer
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Birmingham, AlabamaAges 18–79 - NCT04621435RecruitingPhase 1
PET imaging test for solid tumors using FAP-2286
This Phase 1 study tests a special imaging scan (using FAP-2286) to see solid tumors in people who have already been diagnosed. It may help doctors better detect where cancer is in the body and how to plan treatment.
San Francisco, CaliforniaAges 18 years+ - NCT04585958RecruitingPhase 1
Combination treatment for HER2-positive cancers and resistant ovarian cancer
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT04499365RecruitingEarly Phase 1
PET scan for detecting different cancer types
This trial uses a special PET scan to see how well it can find and track different types of cancer. It may help doctors better understand your cancer.
Fuzhou, FujianAges 18–90 - NCT04505618Recruiting
Eye scan study using special imaging for blood-vessel disease
This study uses a detailed eye scan (optical coherence tomography angiography) to look at how blood vessels in the retina are affected. It may help researchers better understand retinal vascular diseases, though some people will be excluded for safety or image-quality reasons.
Baltimore, MarylandAges 18–99
Hear when a new Tomography trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tomography?
- Yes. Clin2 currently lists 842 recruiting tomography studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tomography trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tomography trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.